Small Pharmaceuticals
Market Cap
₹32,845 ₹32,845 Cr.
P/E
80.30
PEG
1.76
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Bull case hinges on securing a tier-1 out-licensing partner for Zaynich that accelerates US/EU penetration and adds upfront milestones, while bear case materializes if FDA issues a Complete Response Letter delaying launch beyond FY29.

The mix shift from generics (56% of FY26) to innovative NCEs (41% by FY31) is the central growth engine, with each delay in NCE commercialization directly compressing revenue and margin expansion.

Biotech capacity doubling to capture the disposable insulin vacuum left by Novo Nordisk provides a secondary growth leg, but pricing pressure from entrenched players could cap gains.

  • Wockhardt
  • Ajanta Pharma
  • Caplin Point Labs.
  • TJI Pharma - Small Cap

FAQs on Wockhardt Ltd. Shareprice

Wockhardt has given better returns compared to its competitors.
Wockhardt has grown at ~40.01% over the last 5yrs while peers have grown at a median rate of 12.45%

Wockhardt is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Wockhardt is 80.3, while 3 year average PE is 54.93.
Also latest EV/EBITDA of Wockhardt is 44.97 while 3yr average is 101.

Growth Table

  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Balance Sheet

  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Cash Flow

  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Quarterly Results

  • Wockhardt Ltd.
  • Ajanta Pharma
  • Caplin Point Labs.

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*

FAQs on Wockhardt Ltd. Financials

Balance sheet of Wockhardt is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Wockhardt is increasing.
Latest net debt of Wockhardt is ₹1,625 Crs as of Mar-26.
This is greater than Mar-25 when it was ₹1,477 Crs.

Yes, profit is increasing.
The profit of Wockhardt is ₹414 Crs for TTM, ₹213 Crs for Mar 2026 and -₹47 Crs for Mar 2025.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Wockhardt latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech